Krishidhan Seeds Limited

Our R&D activities and research centers are recognized by the Department of Scientific and Industrial Research (DSIR), Govt. of India. We see ourselves emerging as one of the biggest technology driven Indian agricultural input company with a significant global presence, providing access to latest technologies and all required quality agricultural inputs for the socio economic growth of farmers worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

THERMO FISHER SCIENTIFIC OPENS BIOPROCESSING MANUFACTURING SITE IN OGDEN, UTAH

Thermo Fisher Scientific | April 21, 2022

news image

Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity ...

Read More

INDUSTRIAL IMPACT

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

news image

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

news image

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

news image

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More
news image

MEDICAL

THERMO FISHER SCIENTIFIC OPENS BIOPROCESSING MANUFACTURING SITE IN OGDEN, UTAH

Thermo Fisher Scientific | April 21, 2022

Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity ...

Read More
news image

INDUSTRIAL IMPACT

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More
news image

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More
news image

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us